Implementation of dupilumab in routine care of atopic eczema. Results from the German national registry TREATgermany

The German atopic eczema (AE)-registry TREATgermany is a non-interventional multicenter patient cohort study for adult patients with currently moderate-to-severe disease activity or current/previous anti-inflammatory systemic treatment.(1,2) Dupilumab has demonstrated to be an effective treatment for patients with moderate-to-severe AE in clinical trials.(3-5) Real world evidence is now needed to evaluate its effectiveness and safety in routine care.